Dermatológia pre prax 2/2023

Upadacitinib in the treatment of atopic dermatitis

Atopic dermatitis (AD; atopic eczema) is an inflammatory, itchy, chronic or chronically relapsing skin disease. Janus kinase (JAK) inhibitors are a new effective modality for the treatment of AD. Upadacitinib is a selective JAK1 inhibitor indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older who are candidates for systemic therapy. The efficacy and safety of upadacitinib 15 mg and 30 mg once daily were demonstrated in three randomized, double-blind, multicenter Phase 3 clinical trial (MEASURE UP 1, MEASURE UP 2 and AD UP). In the Phase 3 HEADs UP clinical trial, upadacitinib 30 mg once daily achieved a statistically significant improvement in the primary endpoint EASI75 at week 16 versus dupilumab 300 mg administered once every two weeks. The safety of treatment with JAK inhibitors is strictly monitored, JAK inhibitors should be used with caution in patients with risk factors.

Keywords: atopic dermatitis, treatment, upadacitinib